NZ722287B2 - Automatic injection devices having overmolded gripping surfaces - Google Patents
Automatic injection devices having overmolded gripping surfaces Download PDFInfo
- Publication number
- NZ722287B2 NZ722287B2 NZ722287A NZ72228712A NZ722287B2 NZ 722287 B2 NZ722287 B2 NZ 722287B2 NZ 722287 A NZ722287 A NZ 722287A NZ 72228712 A NZ72228712 A NZ 72228712A NZ 722287 B2 NZ722287 B2 NZ 722287B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- width
- housing
- exemplary
- injection device
- overmolded
- Prior art date
Links
- 239000007924 injection Substances 0.000 title claims abstract description 160
- 238000002347 injection Methods 0.000 title claims abstract description 153
- 238000007689 inspection Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 description 38
- 239000000463 material Substances 0.000 description 31
- 238000010304 firing Methods 0.000 description 29
- 229920002725 Thermoplastic elastomer Polymers 0.000 description 12
- 229920001169 thermoplastic Polymers 0.000 description 12
- 239000004416 thermosoftening plastic Substances 0.000 description 12
- 108090001123 antibodies Proteins 0.000 description 11
- 102000004965 antibodies Human genes 0.000 description 11
- 230000000875 corresponding Effects 0.000 description 10
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 10
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 7
- 230000002093 peripheral Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 108010007562 Adalimumab Proteins 0.000 description 3
- HYNPZTKLUNHGPM-KKERQHFVSA-N Becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 3
- 108010081589 Becaplermin Proteins 0.000 description 3
- 102100007815 PDGFB Human genes 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 229960002964 adalimumab Drugs 0.000 description 3
- 238000004026 adhesive bonding Methods 0.000 description 3
- 229960004787 becaplermin Drugs 0.000 description 3
- 230000001808 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000000994 depressed Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- -1 poly(ethylene terephthalate) Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 230000021317 sensory perception Effects 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- 229960000533 Dornase alfa Drugs 0.000 description 2
- 229940048921 Humira Drugs 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229940107568 Pulmozyme Drugs 0.000 description 2
- 229940116157 Regranex Drugs 0.000 description 2
- 230000001627 detrimental Effects 0.000 description 2
- 108010067396 dornase alfa Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920005669 high impact polystyrene Polymers 0.000 description 2
- 239000004797 high-impact polystyrene Substances 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000011528 polyamide (building material) Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- WUWDLXZGHZSWQZ-WQLSENKSSA-N (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 108010061171 Abatacept Proteins 0.000 description 1
- 229940099550 Actimmune Drugs 0.000 description 1
- 229940099983 Activase Drugs 0.000 description 1
- 229940022705 Aldurazyme Drugs 0.000 description 1
- 108010090726 Alefacept Proteins 0.000 description 1
- 229940115115 Aranesp Drugs 0.000 description 1
- 229940094361 Arcalyst Drugs 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 229940090047 Auto-Injector Drugs 0.000 description 1
- 229940021459 Betaseron Drugs 0.000 description 1
- 229940089093 Botox Drugs 0.000 description 1
- 229940094657 Botulinum Toxin Type A Drugs 0.000 description 1
- 108010043024 Botulinum Toxins Proteins 0.000 description 1
- 229940009550 C1 esterase inhibitor Drugs 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- 229940088949 Cinryze Drugs 0.000 description 1
- 229940076664 Close Up Drugs 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 229940012882 Elaprase Drugs 0.000 description 1
- 229940053603 Elitek Drugs 0.000 description 1
- 229940073038 Elspar Drugs 0.000 description 1
- 229940073621 Enbrel Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 229960003388 Epoetin alfa Drugs 0.000 description 1
- 229940089118 Epogen Drugs 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 229940014516 Fabrazyme Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100008356 IDS Human genes 0.000 description 1
- 102100005044 IL11 Human genes 0.000 description 1
- 229940090438 Infergen Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 229960004461 Interferon beta-1a Drugs 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 229940028862 Interferon gamma-1b Drugs 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 229940065638 Intron A Drugs 0.000 description 1
- 229940065223 Kepivance Drugs 0.000 description 1
- 229940054136 Kineret Drugs 0.000 description 1
- 229940029238 Mircera Drugs 0.000 description 1
- 229940112646 Myobloc Drugs 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 229940103023 Myozyme Drugs 0.000 description 1
- 229940068704 Naglazyme Drugs 0.000 description 1
- 229940071846 Neulasta Drugs 0.000 description 1
- 229940082926 Neumega Drugs 0.000 description 1
- 229940029345 Neupogen Drugs 0.000 description 1
- 229940024236 Nplate Drugs 0.000 description 1
- 229940100027 Ontak Drugs 0.000 description 1
- 229940035567 Orencia Drugs 0.000 description 1
- 229960002404 Palifermin Drugs 0.000 description 1
- 229940002988 Pegasys Drugs 0.000 description 1
- 229960001373 Pegfilgrastim Drugs 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229940071643 Prefilled Syringe Drugs 0.000 description 1
- 229940087463 Proleukin Drugs 0.000 description 1
- 229960000424 Rasburicase Drugs 0.000 description 1
- 229940038850 Rebif Drugs 0.000 description 1
- 229940116243 Retavase Drugs 0.000 description 1
- 229960002917 Reteplase Drugs 0.000 description 1
- 101710038979 SBXA1 Proteins 0.000 description 1
- 229960000216 Tenecteplase Drugs 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 229940113038 Tnkase Drugs 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- 108010056760 agalsidase beta Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229960004593 alglucosidase alfa Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003288 anthiarrhythmic Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 230000000881 depressing Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940056176 drotrecogin alfa Drugs 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 229960005390 galsulfase Drugs 0.000 description 1
- 108010089296 galsulfase Proteins 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 108010086781 golimumab Proteins 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 108010072166 idursulfase Proteins 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229960002486 laronidase Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003219 poly( p-phenylene oxide) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010017584 romiplostim Proteins 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000103 thrombolytic agents Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150259—Improved gripping, e.g. with high friction pattern or projections on the housing surface or an ergonometric shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150274—Manufacture or production processes or steps for blood sampling devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2026—Semi-automatic, e.g. user activated piston is assisted by additional source of energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
- A61M2205/584—Means for facilitating use, e.g. by people with impaired vision by visual feedback having a color code
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/586—Ergonomic details therefor, e.g. specific ergonomics for left or right-handed users
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
- A61M5/3137—Specially designed finger grip means, e.g. for easy manipulation of the syringe rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/3157—Means providing feedback signals when administration is completed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Abstract
injection device (100) is disclosed. The injection device (100) comprises: a housing (101) having a first body portion (116) cooperatively engageable with a second body (118) portion to define a cavity therein; a proximal portion (106) of the housing (101) adapted to be gripped by a user which includes a first width at a proximal terminal end, a second width adjacent to a neck portion, and a third width at the neck portion; a distal portion (104) of the housing adapted to perform an injection includes a fourth width; a first aperture (119) formed in the first body portion (116); and a second aperture (127) formed in the first body portion (116). cludes a first width at a proximal terminal end, a second width adjacent to a neck portion, and a third width at the neck portion; a distal portion (104) of the housing adapted to perform an injection includes a fourth width; a first aperture (119) formed in the first body portion (116); and a second aperture (127) formed in the first body portion (116).
Description
AUTOMATIC INJECTION DEVICES HAVING OVERMOLDED GRIPPING
SURFACES
BACKGROUND
Automatic injection devices offer an alternative to manually-operated syringes for
administering therapeutic agents into patients’ bodies and allowing patients to self-administer
therapeutic agents. Automatic injection devices may be used to administer medications under
emergency conditions, for example, to administer epinephrine to counteract the effects of a
severe allergic reaction. Automatic injection devices have also been described for use in
administering anti-arrhythmic medications and selective thrombolytic agents during a heart
attack. See, for example, U.S. Patent Nos. 3,910,260; 4,004,577; 4,689,042; 4,755,169; and
4,795,433, the entire contents of which are incorporated herein in their entirety by reference.
Various types of automatic injection devices are also described in, for example, U.S. Patent Nos.
3,941,130; 4,261,358; 5,085,642; 5,092,843; 5,102,393; 5,267,963; 6,149,626; 6,270,479; and
6,371,939; and International Patent Publication No. WO/2008/005315, the entire contents of
which are incorporated herein in their entirety by reference.
Conventionally, an automatic injection device houses a syringe and, when operated,
causes the syringe to move forwardly and a needle to project from the housing so that a
therapeutic agent contained in the syringe is ejected into a patient’s body.
SUMMARY OF INVENTION
Accordingly, the present invention provides in one aspect an injection device,
comprising:
a housing having a first body portion cooperatively engageable with a second body
portion to define a cavity therein;
a proximal portion of the housing adapted to be gripped by a user includes a first width
at a proximal terminal end thereof, a second width adjacent to a neck portion, and a third width
at the neck portion;
a distal portion of the housing adapted to perform an injection includes a fourth width;
a first aperture formed in the first body portion; and
a second aperture formed in the first body portion.
14247263_1:hxa
Exemplary embodiments provide automatic injection devices, housing components for
automatic injection devices and methods for fabricating the same. An exemplary housing of an
automatic injection device may be overmolded with one or more gripping surfaces to facilitate
gripping and manipulation of the automatic injection device by a user when performing an
injection. In an exemplary embodiment, an overmolded left gripping surface may extend along a
left side of the housing and an overmolded right gripping surface may extend along a right side
of the housing opposite to the left side.
In accordance with an exemplary embodiment, an automatic injection device is provided
with a housing enclosing a cavity for accommodating a container. A first overmolded gripping
surface is provided to extend longitudinally along a portion of the housing on a first exterior
surface of the housing. A second overmolded griping surface is provided to extend
longitudinally along a portion of the housing on a second exterior surface of the housing
opposite to the first exterior surface.
In an exemplary embodiment, the first and second overmolded gripping surfaces on the
housing are formed of a first material having a first touch perception, and non-gripping surfaces
on the housing are formed of a second material having a second touch perception. In an
exemplary embodiment, the first and second overmolded gripping surfaces on the housing are
formed of a first material having a first hardness, and non-gripping surfaces on the housing are
formed of a second material having a second higher hardness.
In an exemplary embodiment, the automatic injection device includes a removable distal
cap for protectively covering an injection needle couplable to the container, an exterior surface
of the distal cap including an overmolded gripping surface for facilitating gripping and removal
of the
14247263_1:hxa
distal cap. In an exemplary embodiment, the automatic injection device includes a firing button
protruding from an aperture in the housing and including an overmolded contact surface for
facilitating actuation of the firing button by a user. In an exemplary embodiment, the automatic
injection device includes a proximal terminal end for covering a proximal end of the automatic
injection device, the proximal terminal end having an overmolded exterior surface. In an exemplary
embodiment, a top surface of the proximal terminal end includes a recessed surface for directing
and facilitating accommodation of a user’s hand or finger for gripping the automatic injection
device.
In accordance with another exemplary embodiment, a method is provided for assembling an
automatic injection device. The method includes providing a housing enclosing a cavity for
accommodating a container. The method includes overmolding, on the housing, a first gripping
surface extending longitudinally along a portion of the housing on a first exterior surface of the
housing. The method also includes overmolding, on the housing, a second gripping surface
extending longitudinally along a portion of the housing on a second exterior surface of the housing
opposite to the first exterior surface.
In an exemplary embodiment, the first and second gripping surfaces on the housing are
formed of a first material having a first touch perception, and non-gripping surfaces on the housing
are formed of a second material having a second touch perception. In an exemplary embodiment,
the first and second gripping surfaces on the housing are formed of a first material having a first
hardness, and non-gripping surfaces on the housing are formed of a second material having a
second higher hardness.
In an exemplary embodiment, the method includes overmolding a gripping surface on an
exterior surface of a distal cap to facilitate gripping and removal of the distal cap, and coupling the
distal cap to a distal end of the housing for protectively covering an injection needle. In an
exemplary embodiment, the method includes overmolding a gripping surface on a firing button to
facilitate activation of the firing button, and providing the firing button within the cavity so that
part of the firing button protrudes from an aperture in the housing.
In an exemplary embodiment, the method includes overmolding a gripping surface on an
exterior surface of a proximal terminal end, and coupling the proximal terminal end to a proximal
AH25(11544659v1) JBL
end of the housing. In an exemplary embodiment, a top surface of the proximal terminal end
includes a recessed surface for directing a user’s hand or finger for gripping the automatic injection
device.
In accordance with another exemplary embodiment, an automatic injection device is
provided including a housing enclosing a cavity for accommodating a container. The housing
includes a first overmolded gripping region, a second overmolded gripping region, and a recessed
region abutting the first and second overmolded gripping regions.
In an exemplary embodiment, the recessed region is disposed between the first and second
overmolded gripping regions. In an exemplary embodiment, a width of the housing at the recessed
region is smaller than a width of the housing at the first overmolded gripping region and a width of
the housing at the second overmolded gripping region. In an exemplary embodiment, the recessed
region lacks a gripping surface.
In an exemplary embodiment, the first overmolded gripping region is formed by a proximal
terminal end of the housing having an exterior surface that is overmolded with a gripping surface.
In an exemplary embodiment, the second overmolded gripping region of the housing has a tapered
tubular structure.
BRIEF DESCRIPTION OF THE DRAWINGS
Preferred embodiments of the present invention will now be described, by way of example
only, with reference to the accompanying drawings wherein:
Figure 1 is a left side perspective view illustrating an exemplary automatic injection device
in which a removable distal cap is removed and pictured separately from the housing of the device.
Figure 2 is a right side perspective view illustrating the exemplary automatic injection
device of Figure 1.
Figure 3 is a left side exploded perspective view of the exemplary automatic injection
device of Figures 1 and 2.
AH25(11544659v1) JBL
Figure 4 is a front view of the exemplary automatic injection device of Figures 1-3.
Figure 5 is a left side view of the exemplary automatic injection device of Figures 1-3, the
right side view being a mirror image of the left side view.
Figure 6A is a front close-up view of an exemplary left gripping surface provided on a first
body portion of the device of Figures 1-3.
Figure 6B is a left side close-up view of the exemplary left gripping surface of Figure 6A.
Figure 7 is a bottom view of an exemplary removable distal cap of the exemplary automatic
injection device of Figures 1-3.
Figure 8 is a top view of an exemplary proximal terminal end of the exemplary automatic
injection device of Figures 1-3.
Figure 9 is a flowchart of an exemplary method for forming an exemplary automatic
injection device.
DESCRIPTION OF EMBODIMENTS
Exemplary embodiments provide automatic injection devices having housings that are
particularly designed and configured for reliable, safe, ergonomic and comfortable handling by
users. Exemplary embodiments also provide housing components for automatic injection devices
that are particularly designed and configured for reliable, safe, ergonomic and comfortable
handling by users. Exemplary embodiments also provide methods for fabricating exemplary
housings for automatic injection devices and automatic injection devices including exemplary
housings.
In one exemplary embodiment, one or more overmolded gripping surfaces may be provided
on an exterior surface of an exemplary automatic injection device housing in order to allow the
device to be easily, comfortably and reliably gripped and manipulated by a user. The exemplary
overmolded gripping surfaces are particularly configured and positioned on the housing to prevent
slippage from the hands of the user, and thereby to avoid injury to the user and others in the
AH25(11544659v1) JBL
vicinity. Furthermore, the exemplary overmolded gripping surfaces are particularly configured and
positioned to be ergonomic and comfortable to use, particularly by physically weak users, for
example, older users, users who suffer from rheumatoid arthritis, and the like.
In user tests performed using exemplary automatic injection devices, test participants
appreciated exemplary overmolded gripping surfaces on the sides of the devices and the relatively
large size and ergonomic shape of the device. The test participants provided high ratings for
handling and grip of exemplary devices, in which the overmolded gripping surfaces were the
primary factor in test participants’ high ratings of exemplary device configurations for handling
and grip, compared to devices without overmolded gripping surfaces. For several usability factors,
there was a significant positive correlation between Cochin scores and exemplary device
configurations, which indicates that exemplary devices are well-suited for use by users with hand
dysfunction.
An exemplary automatic injections device may contain and may be used to administer a
dose of a TNFα inhibitor. In an exemplary embodiment, the TNFα inhibitor may be a human
TNFα antibody or antigen-biding portion thereof. In an exemplary embodiment, the human TNFα
antibody or antigen-binding portion thereof may be adalimumab (HUMIRA®) or golimumab.
I. Definitions
Certain terms are defined in this section to facilitate understanding of exemplary
embodiments.
The terms “automatic injection device” and “autoinjector,” as used herein, refer to a device
that enables a patient to self-administer a therapeutically effective dose of a therapeutic agent,
wherein the device differs from a conventional syringe by the inclusion of a mechanism for
automatically delivering the therapeutic agent to the patient by injection when the mechanism is
engaged.
The terms “vessel” and “container,” as used herein, refer to a syringe or cartridge that may
be used in an exemplary automatic injection device for holding a dose of a therapeutic agent.
AH25(11544659v1) JBL
The terms “syringe” and “cartridge,” as used herein, refer to a sterile barrel portion of an
automatic injection device that is filled with a dose of a therapeutic agent prior to distribution or
sale of the device to a patient or other non-medical professional for administration of the
therapeutic agent to a patient. In an exemplary embodiment, a distal end of the barrel portion of a
syringe may be coupled to a sterile hypodermic injection needle. In an exemplary embodiment, a
distal end of the barrel portion of a cartridge may not be coupled to an injection needle. That is, in
exemplary embodiments, a syringe may be a cartridge with a pre-attached injection needle coupled
to its barrel portion.
Exemplary embodiments described herein with reference to a syringe assembly may also be
implemented using a cartridge assembly. Similarly, exemplary embodiments described herein with
reference to a cartridge assembly may also be implemented using a syringe assembly.
The term “pre-filled syringe,” as used herein, refers to a syringe that is filled with a
therapeutic agent immediately prior to administration of the therapeutic agent to a patient, and a
syringe that is filled with a therapeutic agent and stored in this pre-filled form for a period of time
before administration of the therapeutic agent to a patient.
The terms “injection needle” and “needle,” as used herein, refer to a needle in an automatic
injection device that is inserted into a patient’s body to deliver a dose of a therapeutic agent into the
patient’s body. In an exemplary embodiment, the injection needle may be directly coupled to or
may otherwise be in contact with a syringe assembly or a cartridge assembly that holds a dose of
the therapeutic agent. In another exemplary embodiment, the injection needle may be indirectly
coupled to the syringe or cartridge assembly, for example, via a syringe needle and/or a transfer
mechanism that provides fluid communication between the syringe or cartridge assembly and the
injection needle.
The term “pre-injection state,” as used herein, refers to a state of an automatic injection
device prior to activation of the device, i.e., prior to the start of delivery of a therapeutic agent
contained in the device.
The term “injection state,” as used herein, refers to one or more states of an automatic
injection device during the delivery of a therapeutic agent contained in the device.
AH25(11544659v1) JBL
The term “post-injection state,” as used herein, refers to completion of delivery of a
therapeutically effective dose of a therapeutic agent contained in the device, or removal of the
device from the patient prior to completion of delivery of a therapeutically effective dose of the
therapeutic agent.
An automatic injection device provided in accordance with exemplary embodiments may
include a “therapeutically effective amount” or a “prophylactically effective amount” of an
antibody or antibody portion of the invention. A “therapeutically effective amount,” as used
herein, refers to an amount effective, at dosages and for periods of time necessary, to achieve the
desired therapeutic result. A therapeutically effective amount of the antibody, antibody portion, or
other TNFα inhibitor may vary according to factors such as the disease state, age, sex, and weight
of the patient, and the ability of the antibody, antibody portion, or other TNFα inhibitor to elicit a
desired response in the patient. A therapeutically effective amount is also one in which any toxic or
detrimental effects of the antibody, antibody portion, or other TNFα inhibitor are outweighed by
the therapeutically beneficial effects. A “prophylactically effective amount,” as used herein, refers
to an amount effective, at dosages and for periods of time necessary, to achieve the desired
prophylactic result. Typically, since a prophylactic dose is used in patients prior to or at an earlier
stage of disease, the prophylactically effective amount will be less than the therapeutically effective
amount.
The terms “substance” and “therapeutic agent,” as used herein, refer to any type of drug,
biologically active agent, biological substance, chemical substance or biochemical substance that is
capable of being administered in a therapeutically effective amount to a patient employing
exemplary automatic injection devices. Exemplary therapeutic agents usable in exemplary
automatic injection devices may include, but are not limited to, agents in a liquid state. Such agents
may include, but are not limited to, adalimumab (HUMIRA®) and proteins that are in a liquid
solution, e.g., fusion proteins and enzymes. Examples of proteins in solution include, but are not
limited to, Pulmozyme (Dornase alfa), Regranex (Becaplermin), Activase (Alteplase), Aldurazyme
(Laronidase), Amevive (Alefacept), Aranesp (Darbepoetin alfa), Becaplermin Concentrate,
Betaseron (Interferon beta-1b), BOTOX (Botulinum Toxin Type A), Elitek (Rasburicase), Elspar
(Asparaginase), Epogen (Epoetin alfa), Enbrel (Etanercept), Fabrazyme (Agalsidase beta), Infergen
(Interferon alfacon-1), Intron A (Interferon alfa-2a), Kineret (Anakinra), MYOBLOC (Botulinum
Toxin Type B), Neulasta (Pegfilgrastim), Neumega (Oprelvekin), Neupogen (Filgrastim), Ontak
AH25(11544659v1) JBL
(Denileukin diftitox), PEGASYS (Peginterferon alfa-2a), Proleukin (Aldesleukin), Pulmozyme
(Dornase alfa), Rebif (Interferon beta-1a), Regranex (Becaplermin), Retavase (Reteplase),
Roferon-A (Interferon alfa-2), TNKase (Tenecteplase), and Xigris (Drotrecogin alfa), Arcalyst
(Rilonacept), NPlate (Romiplostim), Mircera (methoxypolyethylene glycol-epoetin beta), Cinryze
(C1 esterase inhibitor), Elaprase (idursulfase), Myozyme (alglucosidase alfa), Orencia (abatacept),
Naglazyme (galsulfase), Kepivance (palifermin) and Actimmune (interferon gamma-1b).
The term “dose” or “dosage,” as used herein, refers to an amount of a therapeutic agent,
such as a TNFα inhibitor, which is administered to a patient preferably using the wearable
automatic injection device of the invention. In one embodiment, the dose comprises an effective
amount, for example, including, but not limited to, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80
mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, and 160 mg, of the TNFα inhibitor
adalimumab.
The term “dosing,” as used herein, refers to the administration of a therapeutic agent (e.g.,
an anti-TNFα antibody) to achieve a therapeutic objective (e.g., treatment of rheumatoid arthritis).
The term “dosing regimen,” as used herein, refers to a treatment schedule for a therapeutic
agent, such as a TNFα inhibitor, e.g., a treatment schedule over a prolonged period of time and/or
throughout the course of treatment, e.g. administering a first dose of a TNFα inhibitor at week 0
followed by a second dose of a TNFα inhibitor on a biweekly dosing regimen.
The term “treatment,” as used herein, refers to therapeutic treatment, as well as prophylactic
or suppressive measures, for the treatment of a disorder, such as a disorder in which TNFα is
detrimental, e.g., rheumatoid arthritis.
The term “patient” or “user,” as used herein, refers to any type of animal, human or non-
human, that may be administered a therapeutic agent using exemplary automatic injection devices.
The term “proximal” refers to a portion or end or component of an exemplary automatic
injection device that is farthest from an injection site on a patient’s body when the device is held
against the patient for an injection or for mimicking an injection.
AH25(11544659v1) JBL
The term “distal” refers to a portion or end or component of an exemplary automatic
injection device that is closest to an injection site on a patient’s body when the device is held
against the patient for an injection or for mimicking an injection.
The term “planar” is used herein, in a broad lay sense, to mean exactly planar or
approximately planar within some tolerance from the exactly planar.
The term “concave” is used herein, in a broad lay sense, to mean exactly concave or
approximately concave within some tolerance from the exactly concave.
The term “convex” is used herein, in a broad lay sense, to mean exactly convex or
approximately convex within some tolerance from the exactly convex.
The term “elliptical” is used herein, in a broad lay sense, to mean exactly elliptical or
approximately elliptical within some tolerance from the exactly elliptical.
The term “oval” is used herein, in a broad lay sense, to mean exactly oval or approximately
oval within some tolerance from the exactly oval.
The term “rectangular” is used herein, in a broad lay sense, to mean exactly rectangular or
approximately rectangular within some tolerance from the exactly rectangular.
The term “parallel” is used herein, in a broad lay sense, to mean exactly parallel or
approximately parallel within some tolerance from the exactly parallel.
The term “straight” is used herein, in a broad lay sense, to mean exactly straight or
approximately straight within some tolerance from the exactly straight.
The term “equal” is used herein, in a broad lay sense, to mean exactly equal or
approximately equal within some tolerance.
The term “adjacent” is used herein, in a broad lay sense, to mean immediately adjacent or
approximately adjacent within some tolerance.
AH25(11544659v1) JBL
The term “abut” is used herein, in a broad lay sense, to mean immediately abutting or
approximately abutting within some tolerance.
The term “transverse axis” is used herein to refer to an axis that is substantially
perpendicular to a longitudinal axis.
II. Exemplary Embodiments
Exemplary embodiments are described below with reference to certain illustrative
embodiments. While exemplary embodiments are described with respect to using an automatic
injection device to provide an injection of a dose of a therapeutic agent, one of ordinary skill in the
art will recognize that exemplary embodiments are not limited to the illustrative embodiments and
that exemplary automatic injection devices may be used to inject any suitable therapeutic agent into
a patient. In addition, components of exemplary automatic injection devices and methods of
making and using exemplary automatic injection devices are not limited to the illustrative
embodiments described below.
Figures 1-8 illustrate an exemplary automatic injection device 100 having one or more
overmolded gripping surfaces for facilitating gripping and manipulation of the device. The figures
indicate a longitudinal axis L that runs substantially along the length of the device 100, a first
transverse axis H that runs substantially perpendicular to the longitudinal axis L of the device, and
a second transverse axis V that runs substantially perpendicular to both longitudinal axis L and first
transverse axis H.
In some exemplary embodiments, an exemplary length of the device 100 may be about 4,
4.5, 4.8, 5, 5.5, 6, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.5, 8, 8.5, 9, 9.5, 10 inches, but is not limited to these
exemplary lengths. In some exemplary embodiments, an exemplary width of the device 100 (at its
widest location) may be about 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2,
2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0 inches, but is not limited to these exemplary widths. In
some exemplary embodiments, an exemplary thickness of the device 100 (at its thickest location)
may be about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16,
1.17, 1.18, 1.19, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0
inches, but is not limited to these exemplary thicknesses. In an exemplary embodiment, the device
AH25(11544659v1) JBL
100 may have an exemplary length of about 6.69 inches, an exemplary width of about 1.46 inches
at the widest portion, and an exemplary thickness of about 1.15 inches at the thickest portion. In
another exemplary embodiment, the device 100 may have an exemplary length of about 4.8 inches,
an exemplary width of about 0.8 inches at the widest portion, and an exemplary thickness of about
0.6 inches at the thickest portion. The exemplary dimensions of the recited exemplary devices
allow the device to be conformably and ergonomically held in the grip of a user’s hand. This
allows a user to reliably and comfortably grip and manipulate the device in order to perform an
injection.
Exemplary automatic injection device 100 may include an outer housing 101 for housing a
container, such as a syringe or cartridge. The container may be pre-filled with a dose of a
therapeutic agent to be injected into a patient’s body. The housing 101 of the device, in its
assembled form, may have any suitable size and shape for storing and dispensing the dose of the
therapeutic agent. The assembled housing 101 may have a shape that is designed and configured to
be conformable to a user’s hand and so that the user can comfortably and reliably hold the device
100 during an injection. In an exemplary embodiment, the assembled housing 101 may have an
elongated structure so that its length taken along the longitudinal axis L is much greater than its
width taken along the first transverse axis H and its thickness taken along a second transverse axis
V. An exemplary ratio of the length to the width (at the widest location) of the device may be, but
is not limited to, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, all intermediate ratios, and the like. An
exemplary ratio of the length to the thickness (at the thickest location) of the device may be, but is
not limited to, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, all intermediate ratios, and the like.
Figure 1 is a left side perspective view illustrating an exemplary automatic injection device
100 having an outer housing 101. Figure 2 is a right side perspective view of the exemplary
automatic injection device 100 of Figure 1. In an exemplary embodiment, the housing 101 of the
device 100 may have a tapered tubular structure with a substantially elliptical or oval cross-section.
In the tapered tubular structure, the width of the housing 101 may be larger at a proximal portion
106 of the housing 101 than at a distal portion 104 of the housing 101. The tapered tubular shape
of the exemplary housing allows the device to be streamlined and to be conformably and
ergonomically held in and manipulated by a user’s hand.
AH25(11544659v1) JBL
The housing 101 of the device 100 may be formed of a plurality of body components that
are assembled together. In an exemplary embodiment, the housing 101 may be formed from a first
body portion 116 and a second body portion 118 that, when cooperatively engaged to each other
along their peripheral edges, enclose and provide a cavity therebetween. The first and second body
portions may be cooperatively engaged to each other using any suitable technique including, but
not limited to, bonding, gluing, ultrasonic welding, friction fit, snap fit, interference fit, screws,
attachment between corresponding protrusions and recesses, and the like. One of ordinary skill in
the art will recognize that, in other exemplary embodiments, the cavity of the device may be
enclosed in a single body component or in three or more body components when assembled
together.
A firing button 120 may extend from a surface of the first body portion 116. The firing
button 120, when activated by a user, may cause an injection to be performed by the device 100. In
an exemplary embodiment, a recessed or concave portion 126 may be provided on the first body
portion 116 abutting the firing button 120 to facilitate activation of the firing button 120. The
recessed portion 126 may surround the firing button 120 in an exemplary embodiment to
accommodate a user’s finger as the user presses on the firing button 120.
A transparent inspection window 128 may be provided in a surface of the first body portion
116 to allow a user to view the contents of the device 100. The transparent inspection window 128
may allow the user to view a therapeutic agent contained in the device 100, for example, to ensure
clarity of the agent, and to view an end-of-injection indicator that materializes at the end of a
successful injection. An exemplary inspection window 128 may be substantially elongated in
shape, for example, an elongated rectangle (with sharp or rounded edges), an elongated elliptical
shape, and the like, although other shapes are possible. In the elongated inspection window 128,
the length extending along the longitudinal axis L may be substantially greater than the width
extending along the first transverse axis H. In exemplary embodiments, a ratio between the length
and the width of the inspection window may include, but is not limited to, 1.5:1, 2.0:1, 2.5:1, 3.0:1,
3.5:1, 4.0:1, 4.5:1, 5:1, all intermediate ratios, and the like.
A proximal terminal end 172 of the device housing may be provided to cover the proximal
end of the device 100. In an exemplary embodiment, the proximal terminal end 172 may be
coupled to the proximal end of the assembled first and second body portions. The proximal
AH25(11544659v1) JBL
terminal end 172 may take any suitable size and shape. In an exemplary embodiment, the proximal
terminal end 172 may have a substantially tubular configuration with a substantially oval or
elliptical shape. In an exemplary embodiment, at least part of the exterior surface of the proximal
terminal end 172 may be overmolded with one or more gripping surfaces 173 to facilitate gripping
of the proximal portion of the device. In an exemplary embodiment, the entire exterior surface of
the proximal terminal end 172 may be covered by an overmolded gripping surface 173.
Corresponding recesses may be provided on the exterior surface of the proximal terminal end 172
to accommodate the gripping surfaces.
A removable distal cap 164 may be coupled to the distal end of the assembled first and
second body portions to cover the distal end of the device 100 in order to prevent exposure of the
injection needle prior to an injection. The distal cap 164 protects against accidental and/or
unwanted contact of a user with the injection needle. The distal cap 164 also protects against
damage to and contamination of the injection needle when the device is not in use. The distal cap
164 may take any suitable size and shape. In an exemplary embodiment, the distal cap 164 may
have a substantially tubular configuration with a substantially oval or elliptical shape. In an
exemplary embodiment, a front surface of the distal cap 164 may have a concave cutout portion
168 for accommodating part of the inspection window 128.
In an exemplary embodiment, the exterior surface of the distal cap 164 may lack
overmolded gripping surfaces. In other exemplary embodiments, the exterior surface of the distal
cap 164 may be overmolded with one or more gripping surfaces 165 for facilitating gripping and
removal of the distal cap 164 from the device. In an exemplary embodiment, the entire exterior
surface of the distal cap 164 may be covered by an overmolded gripping surface 165.
Corresponding recesses may be provided on the exterior surface of the distal cap 164 to
accommodate the gripping surfaces.
In an exemplary embodiment, one or more ridges (that protrude from the exterior surface)
and/or one or more grooves or divots (that are depressed into the exterior surface) may be provided
at the gripping surfaces 165 on the distal cap 164 to further facilitate gripping and manipulation of
the device. The shapes and locations of the ridges and/or grooves may be altered as desired, and
any desired number of ridges and/or grooves may be provided. In an exemplary embodiment, the
ridges and/or grooves may extend substantially perpendicularly to the longitudinal axis L of the
AH25(11544659v1) JBL
device. In an exemplary embodiment, the gripping surfaces 165 may include textured surfaces to
improve the tactile feel and further facilitate firm gripping of the device. In an exemplary
embodiment, the distal cap 164 may include one or more protrusions 170a, 170b (shown in Figure
) that extend outwardly from the front surface and the back surface of the distal cap 164 to further
facilitate gripping of the cap 164.
In an exemplary embodiment, the distal cap 164 may frictionally engage a recessed or
stepped portion of the housing in order to be retained in position on the housing when the device is
not in use. In an exemplary embodiment, the distal cap 164 may include a boss for locking and/or
joining the cap to the housing until the user is ready to perform an injection. Any suitable mating
mechanism may be used in accordance with the teachings of exemplary embodiments.
When the proximal terminal end 172, the first body portion 116 and the second body
portion 118 are assembled together, they form a tapered tubular structure. Side surfaces of the
body portions 116, 118 abutting the gripping surfaces 173 on the proximal terminal end 172 may
include one or more recessed or concave portions 122, 124. In an exemplary embodiment, two
recessed portions 122, 124 may be provided at opposite sides of the device abutting the firing
button 120. The recessed portions allow the hand of the user to be accommodated in a comfortable
position when pressing the firing button 120.
A portion of the body portions 116, 118 abutting the recessed portions 122, 124 may be
overmolded with one or more gripping surfaces 154, 156 to facilitate holding and manipulation of
the device. In an exemplary embodiment, two gripping surfaces 154, 156 may be provided at
opposite side surfaces of the device. A first gripping surface 154 may abut a first recessed portion
122, and a second gripping surfaces 156 may abut a second recessed portion 124. Corresponding
recesses may be provided on the exterior surface of the first body portion 116 to accommodate the
gripping surfaces.
In an exemplary housing for an automatic injection device, a first overmolded gripping
region, a second overmolded gripping region and a recessed region abutting the first and second
overmolded gripping regions may be provided. The first overmolded gripping region, the second
overmolded gripping region and the recessed region may cooperatively provide an ergonomic and
AH25(11544659v1) JBL
comfortable gripping area at which a user may grip the automatic injection device in order to
perform an injection.
In this exemplary embodiment, the first overmolded gripping region may be formed by the
proximal terminal end 172 having an overmolded outer surface or covering. The second
overmolded gripping region may be formed part of the assembly of the first body portion 116 and
the second body portion 118 having one or more overmolded gripping surfaces (for example,
gripping surfaces 154, 156). In an exemplary embodiment, the second overmolded gripping region
may have a substantially tapered tubular structure for providing an ergonomic fit with a user’s
hand. The recessed region abutting the first and second overmolded gripping regions may be
formed by a portion of the assembly of the first body portion 116 and the second body portion 118
that is narrower in width than the first overmolded gripping region and the second overmolded
gripping region. In an exemplary embodiment, the recessed region may be provided between the
first and second overmolded gripping regions. In an exemplary embodiment, the recessed region
may lack any overmolded gripping surfaces.
Figure 3 illustrates an exploded view of the exemplary automatic injection device 100 of
Figures 1 and 2. In an exemplary embodiment, the first body portion 116 may include a
substantially planar front surface (extending substantially along the L-H plane) and left and right
side surfaces (extending substantially along the L-V plane). The front surface of the first body
portion 116 may contiguously and integrally transition to left and right side surfaces of the first
body portion 116. The edges at which the front surface transitions to the side surfaces may be
sharp, or smooth and rounded in order to maintain a streamlined shape of the device and for
ergonomic handling of the device. The front and/or side surfaces of the first body portion 116 may
be substantially flat or slightly convex so that the assembled housing ergonomically fits within a
user’s hand. The front surface may be wider at the proximal portion 106 of the device than at the
distal portion 104. One of ordinary skill in the art will recognize that other exemplary shapes are
possible for the first body portion 116 of the device.
In an exemplary embodiment, the second body portion 118 may include a substantially
planar front surface (extending substantially along the L-H plane) and left and right side surfaces
(extending substantially along the L-V plane). The front surface of the second body portion 118
may contiguously and integrally transition to left and right side surfaces of the second body portion
AH25(11544659v1) JBL
118. The edges at which the front surface transitions to the side surfaces may be sharp, or smooth
and rounded in order to maintain a streamlined shape of the device and for ergonomic handling of
the device. The front and/or side surfaces of the second body portion 118 may be substantially flat
or slightly convex so that the assembled housing ergonomically fits within a user’s hand. The front
surface may be wider at the proximal portion 106 of the device than at the distal portion 104. One
of ordinary skill in the art will recognize that other exemplary shapes are possible for the second
body portion 118 of the device.
As illustrated in Figure 3, the first body portion 116 and the second body portion 118 may
be cooperatively engaged to each other along their peripheral edges to enclose and provide a cavity
102 therebetween. The upper and second body portions may be cooperatively engaged to each
other using any suitable technique including, but not limited to, bonding, gluing, ultrasonic
welding, friction fit, snap fit, interference fit, screws, attachment between corresponding
protrusions and recesses, and the like. One of ordinary skill in the art will recognize that, in other
exemplary embodiments, the cavity 102 of the device may be enclosed in a single body component
or in three or more body components when assembled together.
An exemplary container 160 is preferably slidably positioned in the cavity 102 and is
coupled to an injection needle (not shown) at a distal end. The injection needle may be covered by
a needle shield 162, for example, a soft needle shield and/or a rigid needle shield. A container
advancement mechanism may be provided within the housing to mechanically advance the
container 160 within and relative to the housing and to eject the therapeutic agent from the
container 160 for performing an injection. The container advancement mechanism may include one
or more actuators (e.g., one or more biasing members) that move the container from a sheathed
position to a projecting position. When the device is in a pre-injection state, the container 160 may
be in a sheathed position, i.e., retracted within the housing. When the device is actuated, the
container advancement mechanism may advance the container 160 to a projecting position so that
the injection needle projects from a distal end of the housing to allow ejection of the therapeutic
agent into a patient’s body. The distal end of the housing may include an aperture through which
the needle may project.
The cavity 102 within the housing may also accommodate a firing engagement mechanism,
for example, the firing button 120. The firing button 120, when actuated by depressing, activates
AH25(11544659v1) JBL
the container advancement mechanism that, in turn, advances the container 160 toward the
injection site, drives the injection needle into the injection site and delivers the therapeutic agent
into the injection site. In an exemplary embodiment, at least a portion of the exterior surface of the
firing button 120 may be overmolded with one or more rubberized gripping surfaces to facilitate
pressing of the firing button by a user’s finger or hand. In an exemplary embodiment, the entire
exterior surface of the firing button may be covered by an overmolded gripping surface. In an
exemplary embodiment, the gripping surfaces on the firing button 120 may be colored differently
from the non-gripping surfaces to provide a visual affordance to indicate which area of the device
should be gripped. For example, the one or more gripping surfaces on the firing button 120 may be
green, while all other surfaces on the device may be one or more colors that are not green.
Figure 3 shows that a front surface of the first body portion 116 may include a first aperture
119 through which the firing button 120 may protrude outside the front surface. An exemplary
aperture 119 may be circular to accommodate the firing button 120 with a circular cross-section,
although other shapes are possible. The front surface of the first body portion 116 may include a
second aperture 127 for accommodating the transparent inspection window 128.
As illustrated in Figure 3, in an exemplary embodiment, the removable distal cap 164 may
frictionally engage a recessed or stepped portion 166 of the housing in order to be retained in
position on the housing when the device is not in use.
Figure 4 illustrates a front surface of the first body portion 116 of the exemplary automatic
injection device 100. Figure 5 illustrates a left side view of the first body portion 116 and the
second body portion 118 as assembled in the device 100.
As illustrated in Figure 4, an exemplary automatic injection device 100 may have a tapered
tubular shape with a substantially elongated, elliptical cross-section. The proximal terminal end
172 of the device may have a narrower proximal end (width w1) that broadens slightly and
gradually to a larger width (width w2) at the distal end of the proximal terminal end 172. The
proximal end of the first body portion 116 abutting the proximal terminal end 172 may include one
or more recessed portions 122, 124 at the sides. The recessed portions 122, 124 may create a
narrow necked portion (width w3) that is narrower than the adjacent width (width w2) of the
proximal terminal end 172. At the distal end of the recessed portions 122, 124, the first body
AH25(11544659v1) JBL
portion 116 may widen to the largest width of the device (width W) and may gradually taper to a
narrower width (width w4) near the mid-portion of the device. At the distal portion 104 of the
device, the first body portion 116 may have a substantially uniform narrow width (width w4).
The second body portion 118 may have a substantially similar shape and configuration as
the first body portion 116. As illustrated in Figure 5, in an exemplary embodiment, the removable
distal cap 164 may include one or more protrusions 170a, 170b (shown in Figure 5) that extend
outwardly from the front surface and the back surface of the distal cap 164 to further facilitate
gripping of the distal cap.
One of ordinary skill in the art will recognize that other shapes are possible in exemplary
automatic injection device 100.
As illustrated in Figures 4 and 5, in an exemplary embodiment, a left gripping surface 130
may be provided to partly cover and extend across the left side surface of the first body portion
116, and a right gripping surface 132 may be provided to partly cover and extend across the right
side surface of the first body portion 116. In an exemplary embodiment, each gripping surface 130,
132 may be disposed between the firing button 120 and the inspection window 128. One of
ordinary skill will recognize that other placements of the gripping surfaces 130, 132 are possible.
Similarly, in an exemplary embodiment, a left gripping surface 152 may be provided to partly
cover and extend across the left side surface of the second body portion 118, and a right gripping
surface 153 may be provided to partly cover and extend across the right side surface of the second
body portion 118. When the first and second body portions are assembled, the left gripping
surfaces 130, 152 may form a contiguous left gripping surface 154 on the housing, and the right
gripping surfaces 132, 153 may form a contiguous right gripping surface 156 on the housing. The
left and right contiguous gripping surfaces 154, 156 facilitate reliable and comfortable gripping and
manipulation of the device by a user’s hand, which markedly and surprisingly improves the user
experience of physically weak users, for example, older users and users suffering from rheumatoid
arthritis.
In user tests performed using exemplary automatic injection devices, test participants liked
the overmolded gripping surfaces on the sides of the device, the ridges on the overmolded gripping
surfaces, and the relatively large size and ergonomic shape of the device. Most test participants
AH25(11544659v1) JBL
(58%) strongly preferred the handling and grip of an example automatic injection device of the
present invention. Overall, the example device configuration received a high average rating of 8.1
out of 10.0. The overmolded gripping surfaces were the primary factor in the participants’ high
ratings of the example device for handling and grip. For several usability factors, there was a
significant positive correlation between Cochin scores and the example device of the present
invention with the overmolded gripping surfaces, which indicates that the example device of the
present invention is well-suited for those with hand dysfunction.
One of ordinary skill in the art will recognize that the left and right gripping surfaces may
have different sizes, shapes and configurations than the exemplary sizes, shapes and configurations
shown in Figures 1-8. One of ordinary skill in the art will recognize that more or fewer gripping
surfaces may be provided on exemplary automatic injection devices that the exemplary left and
right gripping surfaces shown in Figures 1-8. One of ordinary skill in the art will also recognize
that one or more gripping surfaces may be positioned on exemplary automatic injection devices in
positions other than the exemplary positions shown in Figures 1-8. Further, one of ordinary skill in
the art will recognize that the outline of each gripping surface may have a smooth, rounded,
streamlined configuration in some exemplary embodiments.
The overmolded gripping surfaces provided in exemplary embodiments may be formed of
any suitable material that provides a first soft and high-friction touch perception to a user, as
compared to the portions of the device that lack an overmolded gripping surface which provide a
second hard and low-friction touch perception to a user. The difference in the sensory perceptions
provides a touch affordance to a user, indicating that the device is to be gripped at regions provided
with the overmolded gripping surfaces.
In an exemplary embodiment, the overmolded gripping surfaces may be formed of a first
type of material having a soft, high-friction touch perception to a user, while the portions of the
device lacking overmolded gripping surfaces may be formed of a second type of material having a
harder, lower-friction touch perception to a user. In an exemplary embodiment, the overmolded
gripping surfaces may be formed of a first material with a lower hardness, while the non-gripping
surfaces may be formed of a second material with a higher hardness.
AH25(11544659v1) JBL
For example, the non-gripping surfaces may be formed of any rigid thermoplastic material
or rigid substrate suitable for use in a medical device application and suitable for providing a hard,
low-friction touch perception to the user. Rigid thermoplastics can include materials such as
polypropylene (PP), polyethylene (PE), polystyrene (PS), high impact polystyrene (HIPS),
polycarbonate (PC), acrynitrile-butadiene-styrene (ABS), poly(ethylene terephthalate) (PET),
polyamide (PA), PC/ABS blend and PPO/PS blends.
Exemplary overmolded gripping surfaces may be formed of materials having any suitable
material grade and hardness for providing a soft, high-friction touch perception to the user.
Exemplary overmolded gripping surface materials may include, but are not limited to, rubber (for
example, having a durometer of 50A in one embodiment), thermoplastic elastomers (TPEs),
thermoplastic vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be
used to form exemplary overmolded gripping surfaces include, but are not limited to, TPEs from
KRAIBURG, the DynaflexTM TPE from PolyOne, the VersaflexTM TPE from PolyOne, the
VersollanTM TPE from PolyOne, the OnFlexTM TPE from Polyone, and the like. Exemplary
thermoplastic vulcanizates that may be used to form exemplary overmolded gripping surfaces
include, but are not limited to, the Santoprene™ thermoplastic from ExxonMobil and the like.
In an exemplary embodiment, the overmolded gripping surfaces may be colored differently
from the non-gripping surfaces to provide a visual affordance to indicate which area of the device
should be gripped. For example, the left and right overmolded gripping surfaces may be maroon in
color while the non-gripping surfaces on the housing may be grey in color.
As illustrated in Figure 5, in an exemplary embodiment, one or more ridges (that protrude
from the exterior surface) and/or one or more grooves or divots (that are depressed into the exterior
surface) 158a, 158b, 158c (as illustrated in Figures 5 and 6B) may be provided at the left
overmolded gripping surface 154 and/or the right overmolded gripping surface 156 to further
facilitate gripping and manipulation of the device. The shapes and locations of the ridges and/or
grooves may be altered as desired, and any desired number of ridges and/or grooves may be
provided. In an exemplary embodiment, the ridges and/or grooves may extend substantially
perpendicularly to the longitudinal axis L of the device. In an exemplary embodiment, the
overmolded gripping surfaces may include textured surfaces to improve the tactile feel and further
facilitate firm gripping of the device.
AH25(11544659v1) JBL
Figure 6A is a front close-up view of an exemplary left overmolded gripping surface 130
provided on a first body portion 116 of the device 100 of Figure 1. Figure 6B is a left side close-
up view of the exemplary left overmolded gripping surface 130 of Figure 6A. The right
overmolded gripping surface 132 of the first body portion 116, the left overmolded gripping
surface 152 of the second body portion 118, and the right overmolded gripping surface 153 of the
second body portion 118 may be similar in structure and configuration.
Referring to Figures 6A and 6B, the left overmolded gripping surface 130 may have a first
longitudinal side 134 that extends on the front surface of the first body portion 116 substantially
along the longitudinal axis L. In an exemplary embodiment, the first longitudinal side 134 of the
left overmolded gripping surface 130 may be substantially linear, while in another exemplary
embodiment, the first longitudinal side 134 may be slightly concave or convex. A proximal end
136 of the first longitudinal side 134 may extend toward and connect with an end 138 of a first
horizontal side 140 of the left overmolded gripping surface 130. The first horizontal side 140 may
extend across the left side surface of the first body portion 116 substantially along the second
transverse axis V, ending at the peripheral edge of the first body portion 116.
In an exemplary embodiment, a connecting side 142 extending between ends 136, 138 may
connect the first longitudinal side 134 to the first horizontal side 140. In an exemplary
embodiment, the first horizontal side 140 may include a beveled edge extending to the first
longitudinal side 134 at an angle to both longitudinal axis L and the first transverse axis H.
In an exemplary embodiment, the first longitudinal side 134 of the left overmolded gripping
surface 130 may be substantially longer than the first horizontal side 140. An exemplary ratio of
the length of the first longitudinal side 134 to the length of the first horizontal side 140 may
include, but is not limited to, about 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, all intermediate ratios, and
the like.
A distal end 144 of the first longitudinal side 134 may extend toward and connect with an
end 146 of a second horizontal side 148 of the left overmolded gripping surface 130. In an
exemplary embodiment, a connecting side 150 extending between the ends 144, 146 may connect
the first longitudinal side 134 to the second horizontal side 148. In an exemplary embodiment, the
connecting side 150 may have a length greater than that of the connecting side 142. In exemplary
AH25(11544659v1) JBL
embodiments, a ratio of the length of the connecting side 150 to the length of the connecting side
142 may include, but is not limited to, 1.5:1, 1.75:1, 2:1, 2.25:1, 2.5:1, 2.75:1, 3:1, 3.25:1, 3.5:1,
3.75:1, 4:1, all intermediate ratios, and the like, but is not limited to these exemplary ratios. The
second horizontal side 148 may extend across the left side surface of the first body portion 116
substantially along the second transverse axis V, ending at the peripheral edge of the first body
portion 116.
In an exemplary embodiment, the first longitudinal side 134 may be substantially longer
than either the first horizontal side 140 or the second horizontal side 148. An exemplary ratio of
the length of the first longitudinal side 134 to the length of either horizontal side may include, but
is not limited to, about 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1, all intermediate
ratios, and the like.
Figure 7 is a bottom view of an exemplary removable distal cap 164 showing the
overmolded gripping surface 165. The overmolded gripping surfaces 165 may be formed of any
suitable material that provides first a soft and high-friction touch perception to a user, as compared
to the portions of the device that lack an overmolded gripping surface which provide a hard and
low-friction touch perception to a user. The difference in the sensory perceptions provides a touch
affordance to a user, indicating that the device is to be gripped at regions provided with the
overmolded gripping surfaces.
In an exemplary embodiment, the overmolded gripping surfaces may be formed of a first
type of material having a soft, high-friction touch perception, while the non-gripping surfaces are
formed of a second type of material having a harder, lower-friction touch perception. Exemplary
overmolded gripping surfaces 165 may be formed of materials having any suitable material grade
and hardness for providing a soft, high-friction touch perception to the user. Exemplary
overmolded gripping surface materials may include, but are not limited to, rubber (for example,
having a durometer of 50A in one embodiment), thermoplastic elastomers (TPEs), thermoplastic
vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be used to form
exemplary overmolded gripping surfaces include, but are not limited to, TPEs from KRAIBURG,
the DynaflexTM TPE from PolyOne, the VersaflexTM TPE from PolyOne, the VersollanTM TPE
from PolyOne, the OnFlexTM TPE from Polyone, and the like. Exemplary thermoplastic
vulcanizates that may be used to form exemplary overmolded gripping surfaces include, but are not
AH25(11544659v1) JBL
limited to, the Santoprene™ thermoplastic from ExxonMobil and the like. In an exemplary
embodiment, the overmolded gripping surfaces 165 may be colored differently from the non-
gripping surfaces to provide a visual affordance to indicate which area of the device should be
gripped. For example, the one or more overmolded gripping surfaces 165 on the distal cap 164 may
be maroon in color while the non-gripping surfaces on the housing may be grey in color.
Figure 8 is a top view of an exemplary proximal terminal end 172 for covering the proximal
end of the housing. In an exemplary embodiment, the exterior surface of the proximal terminal end
172 may lack any overmolded gripping surfaces. In other exemplary embodiments, at least part of
the exterior surface of the proximal terminal end 172 may be overmolded with one or more
gripping surfaces 173 to facilitate gripping of the proximal portion of the device. In an exemplary
embodiment, the entire exterior surface of the proximal terminal end 172 may be covered by an
overmolded gripping surface 173.
The overmolded gripping surfaces 173 may be formed of any suitable material that provides
a first soft and high-friction touch perception to a user, as compared to the portions of the device
that lack an overmolded gripping surface which provide a second soft and low-friction touch
perception to a user. The difference in the sensory perceptions provides a touch affordance to a
user, indicating that the device is to be gripped at regions provided with the overmolded gripping
surfaces.
In an exemplary embodiment, the overmolded gripping surfaces 173 may be formed of a
first type of material having a soft, high-friction touch perception, while the non-gripping surfaces
are formed of a second type of material having a harder, lower-friction touch perception.
Exemplary overmolded gripping surfaces 173 may be formed of materials having any suitable
material grade and hardness for providing a soft, high-friction touch perception to the user.
Exemplary overmolded gripping surface materials may include, but are not limited to, rubber (for
example, having a durometer of 50A in one embodiment), thermoplastic elastomers (TPEs),
thermoplastic vulcanizate (TPV), and the like. Exemplary thermoplastic elastomers that may be
used to form exemplary overmolded gripping surfaces include, but are not limited to, TPEs from
KRAIBURG, the DynaflexTM TPE from PolyOne, the VersaflexTM TPE from PolyOne, the
VersollanTM TPE from PolyOne, the OnFlexTM TPE from Polyone, and the like.
AH25(11544659v1) JBL
Exemplary thermoplastic vulcanizates that may be used to form exemplary overmolded
gripping surfaces include, but are not limited to, the Santoprene™ thermoplastic from ExxonMobil
and the like. In an exemplary embodiment, the overmolded gripping surfaces 173 may be colored
differently from the non-gripping surfaces to provide a visual affordance to indicate which area of
the device should be gripped. For example, the one or more overmolded gripping surfaces 173 on
the proximal terminal end 172 may be maroon in color while the non-gripping surfaces on the
housing may be grey in color.
In an exemplary embodiment, one or more ridges (that protrude from the exterior surface)
and/or one or more grooves or divots (that are depressed into the exterior surface) may be provided
on the exterior surface of the proximal terminal end 172 to further facilitate gripping of the
proximal portion of the device. The shapes and locations of the ridges and/or grooves may be
altered as desired, and any desired number of ridges and/or grooves may be provided. In an
exemplary embodiment, the overmolded gripping surfaces 173 may include textured surfaces to
improve the tactile feel and further facilitate firm gripping of the device. In an exemplary
embodiment, a wrap-around groove 174 may be provided around the circumference of the
proximal terminal end 172 and a concave or recessed surface 176 may be provided at the top of the
proximal terminal end 172 in order to orient and guide a user’s hand and fingers to the device. For
example, the concave or recessed surface 176 may accommodate a finger on the surface 176 while
the user is performing an injection using the device.
In some exemplary embodiments, the housing 101, the removable distal cap 164 and/or the
proximal terminal end 172 of the device 100 may further include graphics, symbols and/or numbers
to facilitate use of the automatic injection device. For example, the distal cap 164 may include a
depiction of an arrow on an outer surface pointing towards the distal end of the device to indicate
how the device should be held relative to the patient (i.e., with the distal end adjacent to the
injection site). One of ordinary skill in the art will recognize that the automatic injection device
may have any suitable graphics, symbols and/or numbers to facilitate patient instruction, or the
automatic injection device may omit such graphics, symbols and/or numbers.
Figure 9 is a flowchart of an exemplary method of assembling an exemplary automatic
injection device. In an exemplary embodiment, a housing of an exemplary automatic injection
AH25(11544659v1) JBL
device may be provided in two or more separate housing components (for example, first and
second body portion) that may be coupled together during assembly of the device.
In step 902, a first body portion of the housing is provided or formed. In step 904, one or
more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the
first body portion to facilitate gripping and manipulation of the device during an injection.
In step 906, a second body portion of the housing is provided or formed. In step 908, one or
more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the
second body portion to facilitate gripping and manipulation of the device during an injection.
In step 910, a proximal terminal end of the housing is provided or formed. In step 912, one
or more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the
proximal terminal end to facilitate gripping and manipulation of the device.
In step 914, a removable distal cap of the housing is provided or formed. In step 916, one or
more gripping surfaces are overmolded on corresponding recesses on the exterior surface of the
distal cap to facilitate removal of the distal cap before performing an injection.
In step 918, a firing button of the housing is provided or formed. In step 920, one or more
gripping surfaces are overmolded on the exterior surface of the firing button to facilitate activation
of the firing button to perform an injection.
In step 922, one or more internal components of the automatic injection device may be
positioned in a cavity defined between the upper and second body portions. Exemplary device
components may include, but are not limited to, a container (e.g., a syringe) pre-filled with a
therapeutic agent for injecting into a patient, an injection needle coupled to a distal end of the
container, a container advancement mechanism for advancing the container within and relative to
the housing toward the injection site and for ejecting the therapeutic agent from the container
during an injection, a firing button for activating the container advancement mechanism, and the
like.
In step 924, the upper and second body portions may be cooperatively engaged to form a
body assembly that encloses and holds the internal components within the cavity. In an exemplary
AH25(11544659v1) JBL
embodiment, the body portions may be coupled at their peripheral edges. Any suitable coupling or
joining may be used in step 924 including, but not limited to, bonding, gluing, ultrasonic welding,
friction fit, snap fit, interference fit, screws, corresponding protrusions and recesses, and the like.
In step 926, the removable distal cap may be removably coupled at a distal end of the body
assembly to cover an injection needle or a needle shield that, in turn, covers the injection needle.
In step 928, the proximal terminal end may be coupled at a proximal end of the body
assembly.
Any suitable fabrication technique may be used to form any of the device components
including, but not limited to, injection molding. The device components may be formed of any
suitable material including, but not limited to, plastics, thermoplastics, polycarbonates, metals, and
the like.
It is noted that the order of the steps discussed herein may be altered as desired and that
other fabrication steps/techniques are possible and are considered within the spirit and scope of the
present invention.
Automatic Injection Device User Tests
Forty-four test participants were recruited to test both the exemplary automatic injection
devices having overmolded gripping surfaces of the present invention and four alternate automatic
injection devices without such gripping surfaces. A majority of the participants were suffering from
rheumatoid arthritis (RA) at the time of the test. The participants were diagnosed with RA from 1
to 40 years ago, with an average age of diagnosis of 9 years ago. Four participants were suffering
from Crohn’s disease at the time of the test.
Test Procedure
Each test participant tested the different exemplary automatic injection device
configurations. In particular, in an example device use phase, each test participant performed a
simulated injection (i.e., an injection with clipped needles and no medicament) using the devices.
After he/she performed a simulated injection, each test participant was asked a series of follow- up
AH25(11544659v1) JBL
questions designed to assess the participant’s approval of the form and function of the devices.
These questions included questions on, for example, the size, shape, ease of handling, comfort of
holding, overall user experience, and the like.
Device Handling and Gripping
Upon performing simulated injections using the different device configurations, test
participants were asked to provide feedback and comparative ratings on handling and grip, overall
ease of use, and comfort in performing the injection steps. All device configurations were rated on
a scale of 1 (very negative) to 10 (very positive).
Most test participants (58%) strongly preferred the handling and grip of the example device
configuration of the present invention, compared to four alternate device configurations that did not
include overmolded gripping surfaces. Test participants particularly liked the rubberized
overmolded grips on the side of the example device and its relatively large size, which made the
example device easy and comfortable to hold. The rubberized overmolded grips were the primary
factor in participants’ high ratings of the example device configuration for handling and grip as
taught herein.
Furthermore, a correlation analysis was performed on hand dysfunction using the Cochin
hand disability scale with the ratings provided for certain usability factors: handling and gripping,
ease of use, ease of starting and performing an injection, comfort of performing injection,
acceptability and overall preference. For several usability factors, there was a significant positive
correlation between Cochin scores and the example device configuration of the present invention,
which indicates that this example device configuration is well-suited for those with hand
dysfunction.
Comfort of Device Holding and Use
Upon performing simulated injections in the example device use phase, test participants
were asked to rate the comfort of holding the example device configuration of the present invention
and four alternate device configurations that did not include any overmolded gripping surfaces.
Test participants rated each device configuration on a scale from 1 (very low confidence) to 7 (very
AH25(11544659v1) JBL
high confidence). Most test participants favored the example device configuration of the present
invention for comfort in performing injection steps, with 45% rating it the highest.
Ease of Device Use And Handling
Upon initial exposure to the example device and before receiving instructions or a
demonstration on use, test participants were asked about the perceived ease of use of the example
device configuration of the present invention and four alternate device configurations that did not
include any overmolded gripping surfaces. Test participants rated each device configuration on a
scale from 1 (very difficult) to 7 (very easy). All of the device configurations received high ratings
for their perceived ease of use.
Upon performing simulated injections in the actual device use phase, test participants were
asked to rate the ease of handling each device configuration. Test participants rated each device
configuration on a scale from 1 (very low confidence) to 7 (very high confidence). Furthermore,
upon performing simulated injections using the device configuration in the third actual device use
phase, test participants were also asked to rate the configurations on their overall ease of use on a
scale of 1 (very difficult) to 10 (very easy).
Most test participants (42%) found the example device configuration of the present
invention easiest to use compared to four alternate device configurations that did not include
overmolded gripping surfaces. Overall, the example device configuration of the present invention
received a high average rating of 7.97 out of 10.0.
Device Size
Upon performing simulated injections in the example device use phase, test participants
were asked to rate the overall size of the example device configuration of the present invention and
four alternate device configurations that did not include any overmolded gripping surfaces on a
scale of 1 (very low confidence) to 7 (very high confidence). All of the device configurations
generally received positive ratings for their overall shape. In general, test participants who
struggled to form a tight fist preferred larger devices. The example device configuration of the
present invention generally received the highest ratings.
AH25(11544659v1) JBL
Device Shape
Upon performing simulated injections in the actual device use phase, test participants were
asked to rate the overall shape of the example device configuration of the present invention and
four alternate device configurations that did not include any overmolded gripping surfaces on a
scale of 1 (very low confidence) to 7 (very high confidence).
All of the device configurations generally received positive ratings for their overall size. In
general, test participants who struggled to form a tight fist preferred larger devices. With respect to
the example device configuration of the present invention, many participants found that the shape
fit nicely in their hand.
III. Incorporation by Reference
The contents of all references, including patents and patent applications, cited throughout
this application are hereby incorporated herein by reference in their entirety. The appropriate
components and methods of those references may be selected for the invention and embodiments
thereof. Still further, the components and methods identified in the Background section are integral
to this disclosure and can be used in conjunction with or substituted for components and methods
described elsewhere in the disclosure within the scope of the invention.
IV. Equivalents
In describing exemplary embodiments, specific terminology is used for the sake of clarity.
For purposes of description, each specific term is intended to, at least, include all technical and
functional equivalents that operate in a similar manner to accomplish a similar purpose.
Additionally, in some instances where a particular exemplary embodiment includes a plurality of
system elements or method steps, those elements or steps may be replaced with a single element or
step. Likewise, a single element or step may be replaced with a plurality of elements or steps that
serve the same purpose. Further, where parameters for various properties are specified herein for
exemplary embodiments, those parameters may be adjusted up or down by 1/20th, 1/10th, 1/5th,
1/3rd, 1/2nd, and the like, or by rounded-off approximations thereof, unless otherwise specified.
Moreover, while exemplary embodiments have been shown and described with references to
particular embodiments thereof, those of ordinary skill in the art will understand that various
AH25(11544659v1) JBL
substitutions and alterations in form and details may be made therein without departing from the
scope of the invention. Further still, other aspects, functions and advantages are also within the
scope of the invention.
Exemplary flowcharts are provided herein for illustrative purposes and are non-limiting
examples of methods. One of ordinary skill in the art will recognize that exemplary methods may
include more or fewer steps than those illustrated in the exemplary flowcharts, and that the steps in
the exemplary flowcharts may be performed in a different order than shown.
AH25(11544659v1) JBL
Claims (12)
1. An injection device, comprising: a housing having a first body portion cooperatively engageable with a second body portion to define a cavity therein; a proximal portion of the housing adapted to be gripped by a user includes a first width at a proximal terminal end thereof, a second width adjacent to a neck portion, and a third width at the neck portion; a distal portion of the housing adapted to perform an injection includes a fourth width; a first aperture formed in the first body portion; and a second aperture formed in the first body portion.
2. The injection device of claim 1, wherein the first aperture is formed in the proximal portion of the housing.
3. The injection device of claim 1, wherein the second aperture is formed in the distal portion of the housing.
4. The injection device of claim 1, wherein a mid-portion of the proximal portion of the housing has a width greater than any of the first width, the second width, the third width, or the fourth width.
5. The injection device of claim 1, wherein the second width is greater than the first width.
6. The injection device of claim 1, wherein the third width is less than the second width.
7. The injection device of claim 1, wherein the housing further comprises a recessed or stepped portion formed in the distal portion.
8. The injection device of claim 6, further comprising a removable cap that frictionally engages with the recessed or stepped portion of the housing.
9. The injection device of claim 4, wherein the width is located at the distal end of the neck portion. 14247263_1:hxa
10. The injection device of claim 1, wherein the fourth width is substantially uniform along an entire length of the distal portion of the device.
11. The injection device of claim 1, wherein the second aperture accommodates an inspection window that is substantially elongated in shape, and wherein a length of the inspection window extending along a longitudinal axis is substantially greater than a width extending along a first transverse axis.
12. The injection device of claim 1, wherein the first aperture and the second aperture are longitudinally aligned along a common surface of the first body portion. AbbVie Biotechnology Ltd. By the Attorneys for the Applicant SPRUSON & FERGUSON Per: 14247263_1:hxa REPLACEMENT SHEET Proximal Portion 106 Distal Portion 104 124 100
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ739694A NZ739694B2 (en) | 2011-01-24 | 2012-01-24 | Automatic injection devices having overmolded gripping surfaces |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161435465P | 2011-01-24 | 2011-01-24 | |
US61/435,465 | 2011-01-24 | ||
NZ711444A NZ711444B2 (en) | 2011-01-24 | 2012-01-24 | Housing for an automatic injection device having overmolded gripping surfaces |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ722287A NZ722287A (en) | 2018-03-23 |
NZ722287B2 true NZ722287B2 (en) | 2018-06-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230158243A1 (en) | Automatic injection devices having overmolded gripping surfaces | |
NZ722287B2 (en) | Automatic injection devices having overmolded gripping surfaces | |
NZ739694B2 (en) | Automatic injection devices having overmolded gripping surfaces | |
NZ711444B2 (en) | Housing for an automatic injection device having overmolded gripping surfaces | |
NZ613299B2 (en) | Automatic injection devices having overmolded gripping surfaces | |
EA040210B1 (en) | DRUG DELIVERY DEVICE ACTIVATED WITH THE PALM OF THE HAND |